摘要
目的研究高尔基磷酸化蛋白-3(GOLPH3)在肺癌组织中的表达,并探讨其对肺癌细胞侵袭和迁移的影响。方法采用免疫组织化学法检测昆明医科大学第一附属医院收集的72例非小细胞肺癌(NSCLC)及61例远癌组织标本中GOLPH3蛋白表达情况。常规培养A549细胞,转染GOLPH3-shRNA质粒和空质粒,建立GOLPH3基因沉默的A549细胞株和对照组细胞。采用划痕实验和Transwell侵袭试验检测各组细胞迁移和侵袭能力。结果 GOLPH3在NSCLC组织的阳性率(58.33%)明显高于远癌组织阳性率(37.70%);同时GOLPH3在TMNⅢ+Ⅳ期组的阳性表达率(74.19%)和淋巴结转移组的阳性表达率(84.21%)明显高于TMNⅠ+Ⅱ期组(46.34%)和淋巴结未转移组(49.06%),差异有统计学意义(P<0.05)。划痕实验结果显示GOLPH3沉默后A549细胞迁移能力减弱,侵袭实验中GOLPH3沉默组比对照组穿膜细胞数减少,差异有统计学意义(P<0.05)。结论肺癌组织中GOLPH3蛋白阳性表达率高,GOLPH3沉默可抑制肺癌细胞侵袭迁移能力。
Objective To study the expression of GOLPH3 in lung cancer and its effect on the invasion and migration of lung cancer cells.Methods The expression of GOLPH3 was detected by immunohistochemistry in 72 NSCLC and 61 paracancerous tissue samples collected from the First Affiliated Hospital of Kunming Medical University.A549 cells were routinely cultured in vitro and transfected with GOLPH3 shRNA plasmid and empty plasmid to establish GOLPH3 gene silencing A549 cell lines and control cell lines.Scratch test and Trans well invasion test were used to detect cell migration and invasion ability.Results The positive expression rate of GOLPH3 in NSCLC tissues(58.33%) was significantly higher than that in paracancerous tissues(37.70%).Meanwhile,the positive expression rate of GOLPH3 in the TMN Ⅲ+Ⅳ group(74.19%) and the lymph node metastasis group(84.21%) was significantly higher than that in the TMN Ⅰ+Ⅱgroup(46.34%) and the lymph node non-metastasis group(49.06%)(P<0.05).Scratch test results showed that the migration ability of A549 cells was weakened after GOLPH3 silencing,and the number of transmembrane cells in the GOLPH3 silenced group was decreased than that in the control group,the difference was statistically significant(P<0.05).Conclusion The positive expression rate of GOLPH3 protein is high in lung cancer tissues.GOLPH3 silencing can inhibit the invasion and migration of lung cancer cells.
作者
王智园
杨曼
刘士岳
苏国苗
雷梓
WANG Zhiyuan;YANG Man;LIU Shiyue;SU Guomiao;LEI Zi(Department of Pathology,The First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,China,650032;Department of Pathology,Fuyuan people's Hospital,Fuyuan,Qujin,Yunnan,China,655500)
出处
《分子诊断与治疗杂志》
2021年第9期1402-1405,1409,共5页
Journal of Molecular Diagnostics and Therapy
基金
国家自然科学地区基金(81660413)
云南省科技厅-昆明医科大学应用基础研究联合专项资金[2019FE001(-219)]
云南省教育厅科学研究基金教师类项目(2018JS201)。